PEPTIDE CORTEXThe library
← The library

Hexarelin

researchGH Axis
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeGH axis
MechanismGhrelin receptor agonist (GHS); among the most potent GH-releasing peptides, with reported desensitisation over continued use
EffectsSignals the GH axis strongly; can affect body composition, fluid retention, cortisol and prolactin
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published2 sourced
Clinical trialDose-response in healthy men (acute GH stimulation)
RouteIntravenous bolus
FrequencySingle bolus
StartingIV boluses of 0.5, 1 and 2 mcg/kg
EscalationNone
TargetGH plateau at about 1.0 mcg/kg; ED50 0.48 mcg/kg

Acute stimulation tests, not a chronic-use regimen. Receptor desensitisation with continued use is documented.

Community protocol — not clinically establishedVendor guide
RouteSubcutaneous
Frequency1-2x daily
StartingNot separately specified
EscalationNone described
Target"1 to 2 mcg/kg per injection", 1-2x daily
Cycle"4 to 8 weeks on, followed by an off period of equal length"

The weight-based figure is borrowed from acute IV GH-stimulation studies, not a chronic-use trial.

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; avoid self-administration; unverified sourcing and purity

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — Studied for cardiac effects independent of GH release, but no outcomes data; any benefit is unproven.